Short answer
OCULAR THERAPEUTIX, INC (OCUL) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Riad Sherif, former Novartis and Alcon executive, elected to Class I board seat through 2027 annual meeting.
OCULAR THERAPEUTIX, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Riad Sherif, former Novartis and Alcon executive, elected to Class I board seat through 2027 annual meeting
- Ophthalmology industry expertise added through Oculis Holding AG CEO and Revenio Group board member
- New director awarded option for 88,000 shares at $6.60 and restricted stock units for 28,000 shares
- Equity awards vest annually over three years, creating potential dilution and aligning director incentives
- Seung Suh Hong resigning effective December 31, 2026, without reported disagreement with management or the board
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other OCULAR THERAPEUTIX, INC 8-K filings
Get the next OCUL 8-K as it lands
Follow OCUL for push alerts, or ask the research agent what this filing means.